论文部分内容阅读
Pancreatic ductal adenocarcinoma （PDAC） is one ofthe most lethal malignancies with a five-year survivalrate of approximately 5%. Several target agents havebeen tested in PDAC, but almost all have failed todemonstrate efficacy in late phase clinical trials